Study identifier:D8480C00032
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open Label Study of the Pharmacokinetics and Safety of cediranib (RECENTINTM, AZD2171) following Single and Multiple Oral Doses in Patients with Advanced Solid Tumours with Various Degrees of Hepatic Dysfunction
Advanced cancer, Hepatic Impairment
Phase 1
No
AZD2171
All
36
Interventional
18 Years - 99 Years
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jul 2014 by AstraZeneca
AstraZeneca
-
To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.
Location
Location
København Ø, Denmark
Location
NIJMEGEN, Netherlands
Location
ROTTERDAM, Netherlands
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: AZD2171 Oral dose Other Name: Cediranib |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.